Main functions and functions of Anamorelin Hydrochloride Tablets

Anamorelin (Anamorelin) is a new oral ghrelin receptor agonist, mainly used to improve weight loss, loss of appetite and muscle wasting in patients with cancer-related cachexia. Cancer cachexia is a metabolic syndrome that is closely related to tumor progression. More than half of patients with advanced cancer are affected by it, manifesting as persistent weight loss, muscle mass loss, and energy metabolism disorders.

The core mechanism of Anamorelin is to simulate the effect of natural ghrelin (Ghrelin) in the human body. By activating the GHS-R1a receptor in the hypothalamus, it stimulates the activity of the appetite center, prompts patients to increase food intake, and promotes the secretion of growth hormone (GH) and insulin-like growth factor (IGF-1), thereby improving lean body mass and nutritional status. This dual effect not only helps patients gain weight, but also improves physical endurance, enhances immune function, and provides a better physiological basis for subsequent anti-tumor treatment.

Unlike traditional appetite-stimulating drugs such as corticosteroids or antidepressants, anamorelin is safer, has less interference with the central nervous system, and will not cause obvious drowsiness or mental side effects. Japan, South Korea and other countries have widely used it in clinical practice as a supportive cancer treatment drug to improve the nutritional status of patients with advanced lung cancer, gastric cancer and pancreatic cancer.

It is worth noting that anamorelin is not a direct anti-cancer drug, but an auxiliary treatment drug to help patients maintain physical fitness and quality of life during long-term treatment. Overseas research is also exploring the potential application of anamorelin in non-cancer diseases, such as chronic obstructive pulmonary disease (COPD), heart failure, and metabolic-related diseases such as senile sarcopenia, which also shows the broad prospects of the drug in delaying debilitating diseases. In the future, with the promotion of the concept of comprehensive cancer management, anamorelin is expected to become an important part of the field of tumor nutritional intervention and provide patients with more treatment options.

Reference materials:https://pmc.ncbi.nlm.nih.gov/articles/PMC4677053/